Member Info for Uncanny

I think people completely missed the potential of the financial enormity of the RNS released yesterday in the extension with Dominion…….

Each of the 3000 FDA approved drugs are basically worth what ever they can be licensed for on any new applications.

Yes, 3000 US FDA approved drugs!

As they’re already approved drugs they’d be fast tracked for access to clinic once they have proof of efficacy so can be licensed pretty quick sharp.

I think this could be massive leap for VAL on top of everything else going on.

You mean this guy,......

"Toby has led and been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value."

You are quite right Kushchall, but it was more an example of how ridiculous a valuation of 0.5p per share is 👍

PLUS royalties……

1p values VAL at just £3.75mn - the 401 deal is worth £16mn on its own as an example.

PS the comment was released by ME “working with….”

Doubt it as it was released 11 hours ago on LinkedIn so still current and the current 6 month extension mean news EOM Nom one way or another.

“Cancer-associated Cachexia is a lethal metabolic syndrome marked by systemic inflammation, CNS appetite dysregulation, & muscle/fat loss—better characterized with imaging. Prevalent in cancers like pancreatic/lung, it's linked to IL-6, GDF-15, & tumor-driven energy drain. Trials targeting CNS and inflammation (e.g., Ghrelin receptor agonist, anti-GDF15 Ab) show promise.“

Very interesting article detailing the complexities of Cancer Associated Cachexia. VALIRX PLC is working with Ambrose Healthcare to develop its phase 2 clinical asset Val401 (https://valirx.com/val401) for treatment of Cachexia https://lnkd.in/eZJMq5j9

Is it the dusk and dawn posting show! LOL

Any reason why l have to sell and exercise or wait 3 years if the price is going in the right direction?

If I wasn't bullish then that would be very strange with my stake, plus I have never said 10p or in fact stipulated any price as I do not have a specific exit strategy in mind, but just letting events unfold.

As for a fund raise, I am cautiously confident we will see the warrants exercised and therefore no need, of which I will 100% exercise my warrants when teh right time comes,

AIMHO NAI GLA DYOR

Are you taking Porky to lunch as well? LOL

This all depends if you are a trader or an investor to all and sundry - short term get out quick rinse / repeat or medium / longer term looking to build wealth now the ship is on track for much larger gains as the IP is licensed out.

It's good cop / bad cop again!

Porky you are so naive - tell me how long does it takes to draft a multi-paged patent document, have it proof read by lawyers and numerous re-drafts and then sent to the GOV.UK intellectual property office for verification and registration?

Yes setting up a basic limited company online using Table A can be done for £40 in 20 minutes but this is an AIM listed PLC with governance, legal sign off requirements and protocol to follow so I would be in total shock if our BoD throw caution to the wind and use 'limitedcompanies4u.com' to place one of its cancer fighting IP peptides in! LOL

The deramp posts are starting to flourish again and as Paternostpauper and Notpotalot say they feel comforted they are invested now as there is no stock and what is in sticky hands, as you can see the desperation kicking by some parties, naming no names but you know who you are

I also concur with Notpotalot saying that "anyone with any doubts should not invest. Very simple. Leave Val to those who have confidence in the Company's future and can accept that mistakes were made in the past." Quite right!

It’s all on the website, hub, presentations and RNS’s my friend along with IMHO estimates of timings but we will see…. GL

We know deal with Ambrose to conclude soon, how long does an SPV and patent take to complete and also ME mentioned the Taiwan connection for 201, recent lab contracts etc by RNS so very much in the public domain so no need to play devils advocate Nick 😂😂😂

Oh well busy few days for me so have a good one and switching off!

certainly no sleep lost patern lol and lets let val do the talking on the pitch with newsflow (unlike sadly ****nal tonight) and not by traders with no idea whatsoever spouting fud on a bb.

grinder 14, what have they got indeed:

8-10 months of money with a further £3.25mn of warrant money to be exercised + 1.3p, with governmental / uni grants achieved to remove and financial burden to val plus vast cost cutting recently rnsd of +£200kpa and large reduction in non operational staff and removal of various board members surplus to needs now.

401 shift from lung to pancreatic ductal adenocarcinoma with 17 worldwide patents advised by external scientific peer group to be monetised via ambrose tba eo may / early june hopefully.

prostate spv (tba) - incorporating 201 preventing the androgen-mediated activation of src kinase, prevents cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or src kinase showing 56% success at ct l/ll this precision method, mimicking a natural process, proposes a high specificity of cancer treatment, with a lower side effect profile, now combined with clx001 tech and in talks with a taiwan outfit, yet free now to market worldwide with a new 20 year global patent tba shortly

clx001 amazing peptide nanoparticle formulation designed for precision destruction of cancer cells to avoid excessive side effects and ind ready by eo 2025 hopefully to be ready to be licensed, with me presenting at 48 bio meets to potential investors since starting his tenure with the most noted being boston with the ip inventor, not playing golf with mates lol

bc201 and 301 on hold (but not closed) with focus on the above being nearest to be monetised .

evaluation pipeline on hold awaiting one of the ip above to be commercialised first and provide a clear financial pathway:

https://valirx.com/evaluation-pipeline and l believ stingray will be the next spv after the 201 / clx prostate spv is updated by rns which should provide a clear value adding inflection point.

inaphaea biolabs: valirx tcro® offering cell-based assays specialising in oncology and women's health to improve the translation of early drug discovery to provide testing services that generate the necessary data, analysis and insights to aid decision-making in translational drug development with 4 collaborations so far including altus plus 4000 vials with a market value of £4mn and to b/e 2025 with wnmorous cost reductions by bringing in house …….

much more to come and 2025 should be an exciting time imho - it’s all on the hub and website if you care to read quite clearly and by official rns of course.

dyor gla nai

I don't ramp I post the facts where as you lie such as CLX is 2 - 3 years away which is not true as is a placing in the coming weeks etc. etc. You use PI's bad fortunes to create strength in your posts which is quite devious for your own personal game and you know it!

You also post the same stuff that Viera does - WFH, golf days, mates rates and the only person that call s me Stephen on here is Nick .... funny that LOL. So stop the deramping and scaremongering and just pay the going rate like everyone else, in fact you can buy at cheaper than the placing now.

*May

Porky, toddle off now and of course there will be no surprises as a loss is bolted on and whether slightly higher or bigger than last year well who gives a fxxx as everyone here is invested to see its IP / SPV's reach key inflection points and add value and thereafter license out and yes, CAB again will have diminished to coin yours and Viera's Favorited phrase 'as night follows day' LOL

We've just started March and plenty of cash to keep things going as it was received in Jan, plus do you know what is going on behind closed doors?

Why not +£10mn?

I think if you forget CLX as a standalone IP for the time being which should be IND ready (so it can be licensed) this year (not 2-3 years like Porky says) and just add up what the cash is plus grants plus cost savings assuming we have used 4 months of money as it arrived Jan, plus £4mn worth of vials and now 4 lab collaborations in motion producing?

If the old THX deal was worth 67mn plus 2.2mn upfront plus 33mn for new additions then what is a new prostate focussed SPV worth taking 201 on a new 20 year patent and bolting on CLX’s amazing tech?

More than what THX offered l’d say plus we know about the Taiwan talks stemming from the China LOI exemption but now ME has more to offer as a robust IP to investors, potentially a larger price tag and free to sell anywhere to anyone!

The new prostate focussed IP should be market ready very soon IMHO and l wonder what interest has already arisen after ME’s 48 x investor bio presentations on CLX et al since he joined as CEO!?

NAI DYOR GLA

seem to be a one handed **** fight going on with two alter egos lol